We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
+40.65%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
10 Year Est. Return
AUM
$281M
AUM Growth
+$40.6M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 79.38%
2 Technology 20.61%
3 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DAWN
1
DELISTED
Day One Biopharmaceuticals
DAWN
$173M 61.6%
9,663,645
AEVA
2
Aeva Technologies
AEVA
$1.26B
$57.9M 20.61%
3,697,039
TYRA icon
3
Tyra Biosciences
TYRA
$1.91B
$31.5M 11.23%
4,409,991
RLYB icon
4
Rallybio
RLYB
$84.6M
$18.2M 6.48%
301,214
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$200K 0.07%
37,051
BRDS
6
DELISTED
Bird Global, Inc.
BRDS
$30K 0.01%
2,771

Similar funds

Canaan Partners XI's Q2 2022 Portfolio in Review

As of Q2 2022, Canaan Partners XI held 6 positions worth $281M, up 17% from $240M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 0%. Canaan Partners XI opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 67% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Canaan Partners XI's ten largest holdings make up 100% of its $281M portfolio in Q2 2022.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q2 2022.
  • Canaan Partners XI's portfolio value rose 17% quarter-over-quarter to $281M.

Based on Canaan Partners XI's 13F filing for Q2 2022, filed 10 Aug 2022.